Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-Sponsored Phase 1/2 Study of Selinexor (KPT-330) and Docetaxel as Second Line Therapy in Patients With Relapsed Squamous Cell Lung Cancer

NCT02536495 is registered in ClinicalTrials.gov with Erin Bertino as lead sponsor.

NCT NCT02536495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02536495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-Sponsored Phase 1/2 Study of Selinexor (KPT-330) and Docetaxel as Second Line Therapy in Patients With Relapsed Squamous Cell Lung Cancer
Lead sponsor
Erin Bertino
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2015
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma